Marja Van Meijer

Title: Marja Van Meijer: Innovator in Myeloid Cell Malignancies

Introduction

Marja Van Meijer is a prominent inventor based in Amsterdam, Netherlands. She has made significant contributions to the field of medical research, particularly in the treatment of myeloid cell malignancies. With a total of four patents to her name, her work focuses on innovative binding molecules that have the potential to revolutionize the diagnosis and treatment of neoplastic disorders.

Latest Patents

Marja's latest patents include groundbreaking work on binding molecules for the treatment of myeloid cell malignancies. These patents provide a human C-type lectin and binding molecules that specifically target this lectin. The inventions also encompass nucleic acid molecules encoding the binding molecules or the human C-type lectin, as well as compositions and methods for identifying or producing these binding molecules. The human C-type lectin is specifically expressed on myeloid cells, and the binding molecules capable of targeting it can be utilized in the diagnosis, prevention, and treatment of various neoplastic disorders and diseases.

Career Highlights

Throughout her career, Marja has worked with notable organizations, including Crucell Holland B.V. and The Johns Hopkins University. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to significant advancements in medical research.

Collaborations

Some of Marja's coworkers include Sonja Van Den Oudenrijn and Alexander Berthold Hendrik Bakker. Their collaborative efforts have further enhanced the impact of her research and innovations.

Conclusion

Marja Van Meijer stands out as an influential inventor in the realm of medical research, particularly in the treatment of myeloid cell malignancies. Her innovative patents and collaborations reflect her commitment to advancing healthcare solutions.